Known targets — ChEMBL curated mechanism
ABCC8ACEADORA1ADORA2AADORA2BADORA3ALDH5A1ALOX5ALOX5APATP4AATP4BBRAFCA1CA12CA2CA4CYSLTR1DHFRDPEP1EDNRAEDNRBESR2F10FDPSFGF1GABBR1GABBR2GABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGARTGNRHRGSC1HMGCRIMPDH1IMPDH2KCNJ11LY96NOD2NR3C1NS3NS4ANS5bP2RY1P2RY12P2RY2P2RY4P2RY6PBP2XPDE3APDE3BPDE4APDE4BPDE4CPDE4DPDK1PDK2PDK3PDK4PPARGPPATPTGIRPTGS1PTGS2RAF1RYR1RYR3SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASERPINC1SLC12A1SLC12A3SYKTHRATHRBTLR3TLR4TLR9TUBA1ATUBA1BTUBA1CTUBA3CTUBA3ETUBA4ATUBBTUBB1TUBB2ATUBB2BTUBB3TUBB4ATUBB4BTUBB6TUBB8TYMSVKORC1XDHblablaIMP-1blaOXA-33blaOXA-58blaT-3blaT-4blaT-5blaT-6dacAdacBdacCfolAfolPfolP1ftsIfusAgaggyrAgyrBmecAmrcAmrcBmrdApbp1apbp1bpbp2pbp2apbp2bpbp3pbp4pbpApbpBpbpCpbpFpolponBrplArplBrplCrplDrplErplFrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmFrpmGrpmHrpmIrpmJrpoArpoBrpoCrpoZrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of None. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 known ✓ | P00915 | 1/20 | 0.31 |
| ▸ | FUT7 | Q11130 | 1/20 | 0.35 |
| ▸ | CTSL | P07711 | 1/20 | 0.32 |
| ▸ | CTSB | P07858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5081937 | 0.77 | CTSL (0.33) | CTSLCTSB | |
| SCHEMBL6129983 | 0.76 | RECQL (0.39) | FUT7CA1 | |
| SCHEMBL7078567 | 0.75 | CTSL (0.32) | CTSLCTSB | |
| SCHEMBL8941058 | 0.72 | RECQL (0.45) | FUT7CA1 | |
| SCHEMBL29329266 | 0.72 | CTSL (0.31) | CTSLCTSB | |
| SCHEMBL9860953 | 0.71 | CA12 (0.31) | CA1 | |
| SCHEMBL28685272 | 0.71 | CTSL (0.35) | FUT7CTSLCTSBCA1 | |
| SCHEMBL8941099 | 0.71 | RECQL (0.48) | FUT7CTSLCTSBCA1 | |
| SCHEMBL5251799 | 0.70 | — | — | |
| SCHEMBL10926822 | 0.70 | G6PD (0.41) | CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-113956249-B | Brain-targeted AChE inhibitor prodrug, and preparation method and application thereof | 中国药科大学 | 2024-02-02 | — | — | CN | disclosed |
| US-10759822-B2 | Brain-targeting prodrug for AMPA receptor synergist, and pharmaceutical applications thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2020-09-01 | — | — | US | disclosed |
| CN-107286114-B | Brain-targeted prodrug of AMPA receptor synergist and medical application thereof | 中国人民解放军军事医学科学院毒物药物研究所 | 2020-08-18 | — | — | CN | disclosed |
| US-20190077821-A1 | Brain-Targeting Prodrug for AMPA Receptor Synergist, and Pharmaceutical Applications Thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2019-03-14 | — | — | US | disclosed |
| EP-3444240-A1 | BRAIN-TARGETING PRODRUG FOR AMPA RECEPTOR SYNERGIST, AND PHARMACEUTICAL APPLICATIONS | Institute of Pharmacology and Toxicology Academy of Military Medical Sciences P.L.A. China (CN) | 2019-02-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10759822-B2 | Brain-targeting prodrug for AMPA receptor synergist, and pharmaceutical applications thereof | GRM3, GRM1, GRM2 | CA1 357/4885FUT7 2937/4885CTSL 3513/4885 |
| US-20190077821-A1 | Brain-Targeting Prodrug for AMPA Receptor Synergist, and Pharmaceutical Applications Thereof | GRM3, GRM1, GRM2 | CA1 357/4885FUT7 2937/4885CTSL 3513/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.